Q&A: Diagnostic Industry Consultant Eric Lawson Discusses Impact of 2011 Regulatory Changes
January 04, 2012
Q&A: Diagnostic Industry Consultant Eric Lawson Discusses Impact of 2011 Regulatory Changes
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Texas Congressman Drafts Bill to Keep Lab Test Oversight out of 'FDA's Lap,' Expand Authority of CMS
October 19, 2011 / Pharmacogenomics Reporter - Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter - Amid 'Chaos,' FDA's Gutierrez Offers Insights on Agency's Regulatory Stance on Molecular Tests
February 13, 2013 / Pharmacogenomics Reporter - Q&A: CDRH's Gutierrez, Mansfield Discuss Ongoing Regulatory Efforts in Personalized Medicine
January 2, 2013 / Pharmacogenomics Reporter - Q&A: Lawyer Jeff Gibbs Discusses Implications of Veterinary Drug Case on FDA's LDT, RUO Guidances
January 18, 2012 / Pharmacogenomics Reporter